Peregrine Ventures today realized the USD 500 million exit from CartiHeal (USD 350 million down payment plus an additional USD 150 million milestone). This exit follows the portfolio company’s Food and Drug Administration (FDA) approval of the Agili-C™ implant for the treatment of cartilage and osteochondral defects. Having achieved this milestone, the medical device company’s…
eTurboNews izindatshana ezababhalisi kuphela. Ukubhalisa kuyinto MAHHALA.
Ababhalisile bangena lapha Chofoza lapha ukuze ubhalise MAHHALA
Ababhalisile bangena lapha Chofoza lapha ukuze ubhalise MAHHALA
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- This exit follows the portfolio company’s Food and Drug Administration (FDA) approval of the Agili-C™ implant for the treatment of cartilage and osteochondral defects.
- Having achieved this milestone, the medical device company’s….
- Ukubhalisa MAHHALA.
